Mantle cell lymphoma (MCL) is an intermediate-grade B-cell lymphoma, representing 2.8% of all non-Hodgkin lymphomas in the US. It is associated with t(11;14)(q13; q23), which leads to the overexpression of cyclin D1, consequently promoting cell proliferation. MCL usually expresses CD19, CD20, CD43, surface immunoglobulins, FMC7, BCL2, cyclin D1, CD5, and SOX11. Herein is a case of a 67-year-old male, referred to our facility with shortness of breath, anemia (hemoglobin of 5.3 g/dL), thrombocytopenia (12 × 10/L), and leukocytosis (283 × 10/L). A peripheral blood smear showed marked lymphocytosis with blastoid morphology. Morphologic examination of the bone marrow biopsy revealed a diffuse sheet of blastoid cells expressing CD20 and CD10, but without CD5 or cyclin D1. Given these features, a differential diagnosis of diffuse large B-cell lymphoma (DLBCL) with germinal center derivation, high-grade follicular lymphoma, and Burkitt lymphoma was considered, with the latter not favored due to morphology. Additional studies revealed positive SOX11, and fluorescence in situ hybridization (FISH) studies detected t(11;14). These additional studies supported diagnosis of the blastoid variant of MCL. In conclusion, we present a unique and challenging case of MCL without cyclin D1 or CD5, but with an expression of CD10 and SOX11, along with t(11;14). Pathologists should explicitly consider the blastoid variant of MCL when dealing with mature B-cell neoplasms with blastoid morphology in adults, and utilize a broad panel of ancillary studies, including FISH and SOX11.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594516 | PMC |
http://dx.doi.org/10.3390/hematolrep15040061 | DOI Listing |
Am J Clin Pathol
December 2024
Mayo Clinic Arizona, Phoenix, AZ, US.
Objectives: High-grade B-cell lymphoma (HGBL), introduced in the 2016 World Health Organization (WHO) revised fourth edition classification, included cases defined by MYC and BCL2 and/or BCL6 rearrangements or by high-grade morphology. Diagnostic criteria and nomenclature for these lymphomas were refined in the 2022 WHO fifth edition (WHO-5) classification and International Consensus Classification (ICC). This review describes our approach to the diagnosis of HGBL.
View Article and Find Full Text PDFInt J Mol Sci
November 2024
Laboratory of Molecular Diagnostics and Cell Biology, College of Veterinary Medicine, Gyeongsang National University, Jinju 52828, Republic of Korea.
Leuk Res Rep
November 2024
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d'hématologie biologique, Pierre-Bénite, France.
This case report presents an 82-year-old male initially diagnosed with classical mantle cell lymphoma (MCL) that progressed to the aggressive blastoid variant. The patient was initially treated with oral chemotherapy (PEP-C), followed by ibrutinib, but experienced disease progression with central nervous system (CNS) involvement and blastoid morphology. Despite subsequent intensive treatment, including high-dose cytarabine (Cytarabine), rituximab, and intrathecal methotrexate (Methotrexate), the patient's disease continued to advance, resulting in death.
View Article and Find Full Text PDFIntern Med J
November 2024
Department of Haematology, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
Mantle cell lymphoma (MCL) is a clinically heterogeneous B-cell neoplasm with unique clinicopathological features, accounting for 5% of all non-Hodgkin lymphoma. Although for many chemoimmunotherapy can lead to durable remissions, those with poor baseline prognostic factors, namely blastoid morphology, TP53 aberrancy and Ki67 >30%, will have less durable responses to conventional therapies. With this in mind, clinical trials have focused on novel targeted therapies to improve outcomes.
View Article and Find Full Text PDFNat Commun
November 2024
Cell Fate Engineering and Therapeutics Lab, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), 61 Biopolis Drive, Proteos, Singapore, 138673, Republic of Singapore.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!